Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $3,658.7M | $3,648.6M | $4,125.4M | $4,802.9M | $5,527.9M | $6,370.0M | $6,772.2M | $5,528.5M | $4,734.2M | $5,370.4M | $2,659.8M | $2,689.4M | $3,458.8M | $2,145.0M | $6,186.8M | $4,974.3M | $6,058.0M | $6,357.1M | $7,127.3M | $10.3B |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Eli Lilly and Company's last 12-month Operating Income is $14.4B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Eli Lilly and Company's Operating Income growth was 144.4%. The average annual Operating Income growth rates for Eli Lilly and Company have been 36.9% over the past three years, 26.1% over the past five years.
Over the last year, Eli Lilly and Company's Operating Income growth was 144.4%, which is higher than industry growth of 0.0%. It indicates that Eli Lilly and Company's Operating Income growth is Good.